PACE-CME

Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction

Clinical benefit with SGLT inhibitor in diabetes patients with HF independent of ejection fraction
RestartResume
3' education - Apr. 8, 2019 - Dr. Eri Kato, Kyoto, Japan
  • Overview

    ACC 2019 In diabetes patients, use of dapagliflozine resulted in clinical benefit regardless of ejection fraction and CV death and total mortality were strongly reduced in HFrEF patients.

  • Educational information

    This video was recorded at the Congress of the American College of Cardiology (ACC) 2019.

  • Faculty

    Dr. Eri Kato is Cardiologist and researcher at the University of Kyoto in Japan.

  • Disclosures

    This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

    The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Facebook Comments

Register

We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free